Skip to main content

menu
menu
person
Search

Interventional Cardiology

Medical & Preventive Cardiology

Lipidology & Atherosclerosis Prevention

CV RISK/DIABETES

A MULTI-SPECIALTY PERSPECTIVE

close

person

Home
Specialties
Submit A Question

Sergio Fazio, MD

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Given the reduction in both CV outcomes and associated, all-cause mortality, are the LDL-C thresholds currently recommended by the AHA and ESC low enough, and what are the implications for PCSK9-mediated CV risk reduction?

Sergio Fazio, MD

Director, Center for Preventive Cardiology

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

Sergio Fazio, MD

Director, Center for Preventive Cardiology

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

Sergio Fazio, MD

Director, Center for Preventive Cardiology

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Sergio Fazio, MD

Director, Center for Preventive Cardiology

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BROADCASTMED